These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35811538)

  • 1. Parkinsonism-Hyperpyrexia Syndrome and Dyskinesia-Hyperpyrexia Syndrome in Parkinson's Disease: Two Cases and Literature Review.
    Wang JY; Huang JF; Zhu SG; Huang SS; Liu RP; Hu BL; Zhu JH; Zhang X
    J Parkinsons Dis; 2022; 12(6):1727-1735. PubMed ID: 35811538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinsonism-hyperpyrexia syndrome: A case report and review of literature.
    Grover S; Sathpathy A; Reddy SC; Mehta S; Sharma N
    Indian J Psychiatry; 2018; 60(4):499-503. PubMed ID: 30581218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinsonism-hyperpyrexia Syndrome After Amantadine Withdrawal: Case Report and Review of the Literature.
    Dos Santos DT; Imthon AK; Strelow MZ; Pille A; Schumacher-Schuh AF
    Neurologist; 2021 Jul; 26(4):149-152. PubMed ID: 34190209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dyskinesia-hyperpyrexia syndrome triggered by overdose of istradefylline: a case report].
    Komori S; Tsuboi T; Suzuki M; Nakamura T; Katsuno M
    Rinsho Shinkeigaku; 2022 Aug; 62(8):627-631. PubMed ID: 35871565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dyskinesia-hyperpyrexia syndrome in a patient with Parkinson's disease: a case report].
    Taguchi S; Niwa J; Ibi T; Doyu M
    Rinsho Shinkeigaku; 2015; 55(3):182-4. PubMed ID: 25786757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhabdomyolysis Associated with Severe Levodopa-Induced Dyskinesia in Parkinson's Disease: A Report of Two Cases and Literature Review.
    Pitakpatapee Y; Srikajon J; Sangpeamsook T; Srivanitchapoom P
    Tremor Other Hyperkinet Mov (N Y); 2021; 11():39. PubMed ID: 34692231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyskinesia-hyperpyrexia syndrome in Parkinson's disease: a systematic review.
    Wang M; Wang W; Gao Z; Yin X; Chen T; Jiang Z; Wang Z
    Clin Auton Res; 2021 Aug; 31(4):529-542. PubMed ID: 33826041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinsonism-hyperpyrexia syndrome after deep brain stimulation surgery: case report.
    Kim JH; Kwon TH; Koh SB; Park JY
    Neurosurgery; 2010 May; 66(5):E1029. PubMed ID: 20404676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The parkinsonism-hyperpyrexia syndrome.
    Newman EJ; Grosset DG; Kennedy PG
    Neurocrit Care; 2009; 10(1):136-40. PubMed ID: 18712508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinsonism-Hyperpyrexia Syndrome: A Case Series and Literature Review.
    Azar J; Jaber Y; Ayyad M; Abu Alia W; Owda F; Sharabati H; Zeid H; Khreshi S; AlBandak M; Sayyed Ahmad D
    Cureus; 2022 Sep; 14(9):e29646. PubMed ID: 36320988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinsonism in essential tremor cases: A clinicopathological study.
    Rajput AH; Rajput EF; Bocking SM; Auer RN; Rajput A
    Mov Disord; 2019 Jul; 34(7):1031-1040. PubMed ID: 31180613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Life-threatening parkinsonism-hyperpyrexia syndrome following bilateral deep brain stimulation of the subthalamic nucleus.
    Akçakaya MO; Akçakaya NH; Kasımcan MÖ; Kırış T
    Neurol Neurochir Pol; 2018 Mar; 52(2):289-292. PubMed ID: 29233537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Not Available].
    Grabli D
    Presse Med; 2017 Mar; 46(2 Pt 1):187-194. PubMed ID: 28233705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment.
    Onofrj M; Bonanni L; Cossu G; Manca D; Stocchi F; Thomas A
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S233-6. PubMed ID: 20082998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.
    Charvin D; Di Paolo T; Bezard E; Gregoire L; Takano A; Duvey G; Pioli E; Halldin C; Medori R; Conquet F
    Mov Disord; 2018 Oct; 33(10):1619-1631. PubMed ID: 30216534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dropped head associated with amantadine in Parkinson disease.
    Kataoka H; Ueno S
    Clin Neuropharmacol; 2011; 34(1):48-9. PubMed ID: 21242745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
    Nicoletti A; Mostile G; Nicoletti G; Arabia G; Iliceto G; Lamberti P; Marconi R; Morgante L; Barone P; Quattrone A; Zappia M
    J Neurol; 2016 May; 263(5):888-894. PubMed ID: 26964541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.